{"transactions":[{"id":949989,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T01:24:52.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003108","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003108/ownership.xml","form_type":"4"}},{"id":949988,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-06T01:24:52.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":4390,"source":{"system":"sec-edgar","filing":"0001193125-26-003108","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526003108/ownership.xml","form_type":"4"}},{"id":1175213,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-04-08T23:05:30.000Z","date":"2025-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1240,"price":24.1474,"value":29942.776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase of shares of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 1,240 shares, with the Reporting Person's sale of shares of the Issuer's common stock at a price of $80.89 per share on October 25, 2024. The Reporting Person has, on a voluntary basis, made arrangements with the Issuer to pay $70,316.25 to the Issuer, representing the full amount of the profit realized in connection with the short-swing transaction, less transactions costs."}],"balance_after":1240,"source":{"system":"sec-edgar","filing":"0000950170-25-052255","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025052255/ownership.xml","form_type":"4/A","original_submission_date":"2025-04-02"}},{"id":1182545,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2025-04-02T22:29:36.000Z","date":"2025-03-31","kind":"purchase","planned":false,"acquired":true,"shares":1240,"price":24.1474,"value":29942.776,"ownership":{"direct":true},"balance_after":1240,"source":{"system":"sec-edgar","filing":"0000950170-25-049717","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025049717/ownership.xml","form_type":"4"}},{"id":1309699,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T01:11:54.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002480","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025002480/ownership.xml","form_type":"4"}},{"id":1381183,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-25T23:28:00.000Z","date":"2024-10-25","kind":"exercise","planned":true,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2024 by the Reporting Person."}],"balance_after":11000,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000950170-24-117514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024117514/ownership.xml","form_type":"4"}},{"id":1381182,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-25T23:28:00.000Z","date":"2024-10-25","kind":"sale","planned":true,"acquired":false,"shares":11000,"price":80.89,"value":889790.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2024 by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-117514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024117514/ownership.xml","form_type":"4"}},{"id":1381181,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-25T23:28:00.000Z","date":"2024-10-25","kind":"exercise","planned":true,"acquired":true,"shares":11000,"price":4.88,"value":53680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2024 by the Reporting Person."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0000950170-24-117514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024117514/ownership.xml","form_type":"4"}},{"id":1653003,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-09T00:38:45.000Z","date":"2024-02-08","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023."}],"balance_after":0,"derivative":{"exercise_price":8.32,"exercise_date":"2020-07-01","expiration_date":"2029-07-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-24-003008","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919124003008/doc4.xml","form_type":"4"}},{"id":1653002,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-02-09T00:38:45.000Z","date":"2024-02-08","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":28.05,"value":701250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-003008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919124003008/doc4.xml","form_type":"4"}},{"id":1653001,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-02-09T00:38:45.000Z","date":"2024-02-08","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":8.32,"value":208000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-24-003008","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919124003008/doc4.xml","form_type":"4"}},{"id":1674952,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-20T01:35:02.000Z","date":"2024-01-19","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023."}],"balance_after":25000,"derivative":{"exercise_price":8.32,"exercise_date":"2020-07-01","expiration_date":"2029-07-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-001973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919124001973/doc4.xml","form_type":"4"}},{"id":1674951,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-20T01:35:02.000Z","date":"2024-01-19","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":23.05,"value":691500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-001973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919124001973/doc4.xml","form_type":"4"}},{"id":1674950,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-20T01:35:02.000Z","date":"2024-01-19","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":8.32,"value":249600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-24-001973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919124001973/doc4.xml","form_type":"4"}},{"id":1686947,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-05T02:25:58.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32000,"derivative":{"exercise_price":18.28,"exercise_date":"2025-01-02","expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-24-000923","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919124000923/doc4.xml","form_type":"4"}},{"id":2065693,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T23:11:06.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":8.52,"exercise_date":"2024-01-03","expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-23-001310","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919123001310/doc4.xml","form_type":"4"}},{"id":2442769,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-06T00:10:21.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-22-001982","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919122001982/doc4.xml","form_type":"4"}},{"id":2640161,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T17:46:07.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":4892,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of quarterly non-employee director fees."}],"balance_after":18242,"source":{"system":"sec-edgar","filing":"0001437749-21-016598","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774921016598/rdgdoc.xml","form_type":"4"}},{"id":2907687,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Stock Option","published_at":"2021-01-14T16:38:22.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"balance_after":2500,"derivative":{"exercise_price":2.28,"exercise_date":"2022-01-13","expiration_date":"2031-01-13","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001437749-21-000731","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774921000731/rdgdoc.xml","form_type":"4"}},{"id":2907686,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-01-14T16:38:22.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant."}],"balance_after":13350,"source":{"system":"sec-edgar","filing":"0001437749-21-000731","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774921000731/rdgdoc.xml","form_type":"4"}},{"id":2914617,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-06T21:38:35.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-21-002119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919121002119/doc4.xml","form_type":"4"}},{"id":3285545,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Stock Option","published_at":"2020-02-07T16:13:14.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":1.06,"exercise_date":"2021-02-06","expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001437749-20-002036","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920002036/rdgdoc.xml","form_type":"4"}},{"id":3285544,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-02-07T16:13:14.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":2500,"price":0.001,"value":2.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant."}],"balance_after":10850,"source":{"system":"sec-edgar","filing":"0001437749-20-002036","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920002036/rdgdoc.xml","form_type":"4"}},{"id":3321395,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-04T00:54:08.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":7.95,"exercise_date":"2021-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-001418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919120001418/doc4.xml","form_type":"4"}},{"id":3470336,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-02T20:20:57.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55000,"derivative":{"exercise_price":8.32,"exercise_date":"2020-07-01","expiration_date":"2029-07-01","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-19-040272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1607678/000120919119040272/doc4.xml","form_type":"4"}},{"id":3517542,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-21T16:10:16.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":3350,"price":1.464,"value":4904.4,"ownership":{"direct":true},"balance_after":8350,"source":{"system":"sec-edgar","filing":"0001437749-19-010580","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919010580/rdgdoc.xml","form_type":"4"}},{"id":3664455,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Stock Option","published_at":"2019-02-12T16:15:28.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":0.25,"exercise_date":"2020-02-07","expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-19-002338","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919002338/rdgdoc.xml","form_type":"4"}},{"id":3664454,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-12T16:15:28.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest on the one-year anniversary of the date of grant."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001437749-19-002338","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919002338/rdgdoc.xml","form_type":"4"}},{"id":3711382,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Stock Option","published_at":"2019-01-03T16:27:44.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":0.75,"exercise_date":"2020-01-02","expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-19-000186","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919000186/rdgdoc.xml","form_type":"4"}},{"id":3711381,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":70255,"kind":"person","name":"Rouan Sarah Kathryn","position":1,"cik":"0001761366","reported_name":"Rouan Sarah Kathryn","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-01-03T16:27:44.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001437749-19-000186","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919000186/rdgdoc.xml","form_type":"4"}}]}